Skip to main content

Table 1 Patients clinical characteristics by furosemide users and non-users

From: Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study

 

Esophageal n (%)

Gastric n (%)

 

Users

Never-users

Users

Never-users

Year of diagnosis

1998–2002

85 (25%)

482 (20%)

116 (31%)

507 (25%)

2003–2007

123 (36%)

789 (33%)

126 (34%)

719 (36%)

2008–2013

135 (39%)

1094 (46%)

130 (35%)

779 (39%)

Age at diagnosis: mean

 

74.5

68.2

76.5

69.6

< 60

25 (7%)

564 (24%)

21 (6%)

408 (20%)

60–69

86 (25%)

755 (32%)

64 (17%)

506 (25%)

70–79

124 (36%)

655 (28%)

150 (40%)

698 (35%)

80+

108 (31%)

391 (17%)

137 (37%)

393 (20%)

Gender

Male

217 (63%)

1611 (68%)

241 (65%)

1368 (68%)

Deprivation quintile

1 (least deprived)

63 (18%)

501 (21%)

68 (18%)

381 (19%)

2

86 (25%)

602 (25%)

93 (25%)

480 (24%)

3

70 (20%)

469 (20%)

61 (16%)

413 (21%)

4

71 (21%)

446 (19%)

81 (22%)

429 (22%)

5 (most deprived)

53 (15%)

346 (15%)

69 (19%)

299 (15%)

Treatment

Surgery

125 (36%)

959 (41%)

181 (49%)

1029 (51%)

Chemotherapy

116 (34%)

1178 (50%)

76 (20%)

784 (39%)

Radiotherapy

108 (31%)

591 (25%)

30 (8%)

130 (6%)

Tumor type

Adenocarcinoma

214 (62%)

1391 (59%)

303 (81%)

1581 (79%)

Squamous

99 (29%)

716 (30%)

<5a

19 (1%)

Others

30 (9%)

258 (11%)

64-69a

405 (20%)

Grade

1

17 (7%)

92 (5%)

18 (7%)

69 (5%)

2

131 (53%)

775 (44%)

103 (40%)

484 (33%)

3

93-98a

892 (50%)

132-137a

892 (61%)

4

<5a

16 (1%)

<5a

17 (1%)

Missing

97

590

114

543

Stage

1

8 (17%)

36 (8%)

7 (16%)

33 (12%)

2

10 (21%)

86 (18%)

9 (21%)

54 (20%)

3

20 (43%)

208 (44%)

8 (19%)

67 (28%)

4

9 (19%)

143 (30%)

19 (44%)

116 (43%)

Missing

296

1892

329

1735

Other medication useb

Statin

133 (39%)

553 (23%)

164 (44%)

479 (24%)

Aspirin

146 (43%)

423 (18%)

132 (35%)

366 (18%)

Smoking

Never

101 (43%)

701 (39%)

103 (39%)

609 (42%)

Former

94 (40%)

621 (35%)

123 (46%)

510 (35%)

Current

42 (18%)

473 (26%)

39 (15%)

318 (22%)

Missing

106

570

107

568

Alcohol consumption

Never

36 (16%)

235 (15%)

51 (20%)

243 (18%)

Former

7 (3%)

63 (4%)

12 (5%)

45 (3%)

Current

184 (81%)

1322 (82%)

191 (75%)

1030 (78%)

Missing

116

745

118

687

BMI

Underweight (< 18.5)

6 (3%)

68 (5%)

<5a

50 (4%)

Normal (18.5–24.9)

63 (29%)

549 (38%)

64-69a

429 (35%)

Overweight (25–29.9)

86 (39%)

531 (37%)

91 (39%)

504 (41%)

Obese (≥30)

63 (29%)

300 (21%)

74 (32%)

238 (19%)

Missing

125

917

138

784

Selected comorbidities

Heart failure

51 (15%)

58 (2%)

64 (17%)

61 (3%)

Myocardial infarction

38 (11%)

124 (5%)

48 (13%)

115 (6%)

Hypertension

187 (55%)

979 (41%)

217 (58%)

826 (41%)

Edema

79 (23%)

185 (8%)

86 (23%)

148 (7%)

  1. aRanges presented for statistical disclosure control
  2. bAfter cancer diagnosis, using a 6 months lag (same as furosemide)